Health authorities across Europe and the UK report a concerning rise in ceftriaxone-resistant gonorrhea, with new data confirming that these drug-resistant strains are now spreading through domestic transmission networks rather than solely via travel. The shift, observed throughout 2025 and early 2026, has prompted urgent calls for enhanced surveillance and testing.
Domestic Transmission Replaces Travel-Linked Patterns
For years, European physicians treating antibiotic-resistant gonorrhea could typically trace the infection to a patient’s recent travel history in Southeast Asia. However, the European Centre for Disease Prevention and Control (ECDC) reports that this pattern has fundamentally changed. Recent assessments reveal that resistant strains are now circulating locally, meaning individuals with no history of international travel are testing positive for infections that resist ceftriaxone, the current first-line treatment for the sexually transmitted infection.
The transition toward sustained domestic transmission has been documented across 12 countries. In Sweden, seven of the 13 resistant cases identified between 2025 and early 2026 were acquired locally. Similarly, Germany recorded two cases in 2026 with no travel history, and Norway identified a cluster in April 2026 where two individuals were directly linked to one another. According to Labcompare, this evolution indicates that resistant strains are becoming established within European sexual networks rather than remaining isolated, imported events.
Rising Case Counts in the UK and France
The United Kingdom has experienced a particularly steep increase in resistant infections. Data from the UK Health Security Agency shows that ceftriaxone-resistant cases in England rose from 13 in 2024 to 29 in 2025, according to Thesun.
Emergence of Sexually Transmitted Shigella and TMVII
The rise in resistant gonorrhea coincides with shifts in other sexually transmitted infections. A study published on July 8, 2026, by researchers at the University of Cambridge identified that Shigella sonnei, a bacterium traditionally linked to food and water contamination, has evolved to spread through sexual networks.
Simultaneously, Minnesota health officials are monitoring an outbreak of a sexually transmitted fungal infection caused by Trichophyton mentagrophytes type VII (TMVII). Since July 2025, the state has identified 13 confirmed cases and 27 suspected cases, all within the Twin Cities metropolitan area. The infection causes rashes on the genitals, buttocks, and limbs. While the risk to the general public remains low, officials are urging clinicians to consider TMVII in patients presenting with ringworm-like rashes associated with sexual contact.
Public Health Recommendations and Surveillance
Health agencies are emphasizing the need for more robust diagnostic capabilities to combat these trends. For gonorrhea, the ECDC is pushing for expanded antimicrobial susceptibility testing to ensure that clinicians can identify resistant strains early. Current guidance for individuals remains consistent: limiting the number of sexual partners, using barrier protection, and seeking prompt medical evaluation for any symptoms.
Patients experiencing symptoms such as unusual discharge, pain during urination, or persistent rashes are encouraged to communicate openly with their healthcare providers regarding their sexual history and potential exposures. If you are experiencing symptoms or have concerns about exposure, consult your healthcare provider for testing and evaluation.
